Gain Therapeutics, Inc. shares rise 3.27% intraday after Perspective Therapeutics presented positive [212Pb]VMT-α-NET study update at ASCO Annual Meeting.

Gain Therapeutics, Inc. rose 3.27% intraday, with Perspective Therapeutics providing an update on the [212Pb]VMT-α-NET study at the 2025 ASCO Annual Meeting. The study showed promising results, with four of the initial seven patients in Cohort 2 experiencing objective responses and seven of nine patients in Cohorts 1 and 2 remaining free from disease progression after more than one year of follow-up. The study also reported a favorable safety profile with no dose-limiting toxicities and no discontinuations.